You are a helpful, respectful, and honest assistant. Always answer as helpfully as possible, while being safe. Your answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content. Please ensure that your responses are socially unbiased and positive in nature. If a question does not make any sense or is not factually coherent, explain why instead of answering something not correct. If you don't know the answer to a question, please don't share false information.
What is Which of the following anticancer drugs are competitive inhibitors of tyrosine kinase ? and explain in detail?
Ans. is 'a' i.e., Imatinib and suntinib Molecular targeted agents Tyrosine kinase inhibitors Competitive inhibitors - Imatinib, Nilotinib, Sunitinib, Dasatinib, Erlotinib, Gefitinib, Lapitinib, Sorafinib (Remember all ends with ' nib'). Monoclonal antibodies - Cetuximab, panitumomab. HER2/neu (ERB B2) inhibitors Monoclonal antibody - Transtuzumab. Targeted antibody - Gemtuzomab (anti CD-33), Rituximab (anti - CD20), Alemtuzumab (anti CD-52). Vascular endothelial growth factor (VEGF) inhibitor - Monoclonal antibody - Bevacizumab. Proteosome inhibitors - Boezomib. Histone deacylase inhibitor - Vorinostat DNA - methyl transferase inhibitor - 5-azacytidine, 2-deoxy-5 azacytidine. All - trans - retinoic acid. Biological response modifier - Recombinant IL-2 (aldesleukin, denileukin).